eXoZymes Inc. (EXOZ) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

for a... It's one of the first times in my career I've seen Everything in this presentation, other than statements of historical fact, will be forward-looking statements. Please read our SEC filings to better understand XoZymes as a business, our risk factors, and as an investment opportunity. Welcome to the quarterly investor call. We've been looking forward to presenting for you and speaking with you all. We are four speakers today. I will open. Tyler will cover the product and platform progress. Damian will cover NCT from a partner selection and the commercialization roadmap perspective. Folad will come and show us the finances, and then I'll end where I can talk about the fundraising we did in Q2 and the strategic perspectives of how we are running XoZymes. I know we today have a good mix of long-term investors and brand new investor candidates. So let me show you how we pitch ExoZymes in 30 seconds. It goes like this. ExoZymes makes highly valuable natural products that until now have been inaccessible. Most of them are molecules somewhat have found in nature, but only in tiny amounts. Enough for people to realize a huge market potential, but no practical way of building a commercial product or business. XoZymes enables these new and valuable nutraceuticals and pharmaceuticals with the next generation of biomanufacturing. I will start the update. by expressing my super excitement about the news we released yesterday. Our R&D team and our product development teams have been super over-performing, and it's setting us up for success with NCT. But Tyler, I'll let you go through that and what it means in practice. Over to you. Hello, I'm Tyler Corman, CSO and co-founder of XoZymes. I'd like to pick up on our recent work with NCT, namely the productivity work and what...